Brokerages Set Alpha Tau Medical Ltd. (NASDAQ:DRTS) PT at $12.60

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has been assigned an average rating of “Hold” from the seven brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $12.60.

DRTS has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Barclays lifted their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. LADENBURG THALM/SH SH upped their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Piper Sandler upped their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. Finally, Zacks Research cut Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st.

Alpha Tau Medical Stock Down 4.2%

Alpha Tau Medical stock opened at $12.18 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical has a fifty-two week low of $2.87 and a fifty-two week high of $14.11. The firm has a fifty day moving average price of $10.45 and a two-hundred day moving average price of $8.24. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -18.18 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, analysts forecast that Alpha Tau Medical will post -0.67 earnings per share for the current year.

Insider Transactions at Alpha Tau Medical

In related news, CFO Raphi Levy sold 32,500 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the transaction, the chief financial officer directly owned 147,680 shares in the company, valued at $1,599,374.40. This represents a 18.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 112,270 shares of company stock worth $1,270,923 over the last 90 days. Insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently bought and sold shares of the business. Apella Capital LLC bought a new stake in Alpha Tau Medical in the 4th quarter valued at $1,892,000. Daytona Street Capital LLC bought a new position in shares of Alpha Tau Medical during the 4th quarter worth about $749,000. Mariner LLC lifted its holdings in shares of Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after acquiring an additional 1,915 shares during the period. Millennium Management LLC boosted its position in shares of Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after acquiring an additional 70,081 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the 1st quarter valued at about $286,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.